Vaxil BioTherapeutics

Vaxil BioTherapeutics, established in 2006 and headquartered in Toronto, Canada, is a biotechnology company specializing in immunotherapy. It develops novel vaccines and treatments for infectious diseases and cancer using a unique drug discovery platform based on signal peptides. The company's lead product, ImMucin, has completed a Phase I/II clinical trial for multiple myeloma treatment. Vaxil is also advancing a tuberculosis vaccine/treatment and a COVID-19 vaccine, with collaborations including The Tel Aviv Sourasky Medical Center and the U.S. Army Medical Research Institute of Infectious Diseases.